Ironwood Pharmaceuticals Q3 revenue beats estimates, raises 2026 outlook

Overview

• U.S. GI therapies maker's Q3 revenue rose year-over-year, beating analyst expectations

• Adjusted EBITDA for Q3 beat analyst expectations

• Company raised full-year 2026 guidance for LINZESS U.S. net sales, revenue and adjusted EBITDA

Outlook

• Company raises 2026 LINZESS U.S. net sales guidance to $1.20-$1.25 bln

• Ironwood raises 2026 total revenue guidance to $485-$510 mln

• Company now expects 2026 adjusted EBITDA of more than $350 mln

Result Drivers

• LINZESS DEMAND - Q3 LINZESS U.S. net sales rose, driven by 4.9% prescription demand growth, partly offset by a low single-digit net price decline

• LOWER EXPENSES - Co reported reduced total costs and expenses year-over-year

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Ironwood Pharmaceuticals, Inc. is $5.35, about 41.9% above its November 4 closing price of $3.77

• The stock recently traded at 3 times the next 12-month earnings vs. a P/E of 3 three months ago

Reuters Recommended Reads

• Nov 2 - Vertex Pharmaceuticals' Q3 revenue slightly beats estimates, outlook raised

• Nov 3 - Pfizer Q3 revenue beats estimates on new launches; raises guidance

• Nov 2 - Neurocrine Biosciences Q3 revenue jumps 41% on strong INGREZZA, CRENESSITY, VYKAT XR demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)